ENANTA PHARMACEUTICALS INC is an SEC registrant, filing under CIK 0001177648, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
ENTA Form 4 activity by transaction type, last 90 days
Form 4 transaction type
Transactions
Shares
Total value
Tax withholding / forfeiture
1
1,467
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ENTA insider transactions (Form 4)
46
53 Form 4 filings on record, the earliest from Nov 27, 2024, newest first. Filing history page 1 of 2.
Footnote F1 (shares): Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022.
Footnote F1 (shares): Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of… Full note on SEC EDGAR
Footnote F2 (shares): Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return… Full note on SEC EDGAR
Footnote F3 (shares): Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Footnote F1 (shares): Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of… Full note on SEC EDGAR
Footnote F2 (shares): Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return… Full note on SEC EDGAR
Footnote F3 (shares): Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Footnote F1 (shares): Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of… Full note on SEC EDGAR
Footnote F2 (shares): Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return… Full note on SEC EDGAR
Footnote F3 (shares): Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Footnote F1 (shares): Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of… Full note on SEC EDGAR
Footnote F2 (shares): Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return… Full note on SEC EDGAR
Footnote F3 (shares): Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Footnote F1 (shares): Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of… Full note on SEC EDGAR
Footnote F2 (shares): Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return… Full note on SEC EDGAR
Footnote F3 (shares): Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Footnote F1 (shares): Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of… Full note on SEC EDGAR
Footnote F2 (shares): Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return… Full note on SEC EDGAR
Footnote F3 (shares): Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Footnote F1 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta… Full note on SEC EDGAR
Footnote F1 (shares): Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.
Footnote F2 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 27, 2024, as required pursuant to the terms of the award. The sale was to satisfy tax withholding… Full note on SEC EDGAR
Footnote F1 (shares): Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.
Footnote F2 (shares): Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 27, 2024, as required pursuant to the terms of the award. The sale was to satisfy tax withholding… Full note on SEC EDGAR
Footnote F1 (shares): Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.
Footnote F1 (shares): Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.
Footnote F1 (shares): Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.
Footnote F1 (shares): Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.
ENANTA PHARMACEUTICALS INC (ENTA) had 1 insider filing in the last 90 days, with the most recent on 2026-08-10. The full record for ENTA runs to 53 Form 4 filings, the earliest from 2024-11-27. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ENTA stock?
No insider purchases of ENTA were filed in the last 90 days.
How many insiders are selling ENTA stock?
No insider sales of ENTA were filed in the last 90 days. 15 sales are on record for this company.
Where can I see ENTA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ENTA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Scott T. Rottinghaus - OfficerOpen-market sale$11K
Kristine Peterson - Director
Mark G. Foletta - Director
Matthew Paul Kowalsky - Officer
